



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

Date: August 09, 2024

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

**Subject: Outcome of the Board Meeting held on Friday, 09<sup>th</sup> August, 2024, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.**

**SYMBOL: AJOONI**

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Friday, 09<sup>th</sup> August 2024 at 02.30 p.m. concluded at 03.00 p.m. Following transactions were considered and approved:

1. Un-audited Financial Results for the quarter ended June 30, 2024.
2. Limited Review Report from the auditor for the quarter ended June 30, 2024.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

Jasjot Singh  
Managing Director  
DIN: 01937631



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

August 09, 2024

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**SYMBOL: AJOONI**

**Sub.: Approval of Un-audited Financial Results for the quarter ended June 30, 2024**

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 09<sup>th</sup> August 2024 at the Registered Office of the company have considered and approved the Un-audited Financial Results for the quarter ended June 30, 2024. In this regard, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter ended June 30, 2024.
2. Limited Review Report from the auditor for the quarter ended June 30, 2024.

You are requested to kindly take the same on record.

Thanking You,  
Yours Truly,  
**For Ajooni Biotech Limited**

**Jasjot Singh**  
**Managing Director**  
**DIN: 01937631**

**AJOONI BIOTECH LIMITED**

**CIN : L85190PB2010PLC040162**

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2024 (In Lakhs)**

PARTICULARS	QUARTER ENDED					Year Ended (Audited)
	30.06.2024	31.03.2024	30.06.2023	Period Ended (UnAudited) 30.06.2024	Period Ended (UnAudited) 30.06.2023	
<b>I Income</b>						
Revenue from operations	2,565.85	1,958.16	2,100.27	2,565.85	2,100.27	8,011.46
Other income	3.67	25.68	7.22	3.67	7.22	219.33
<b>Total income from operations</b>	<b>2,569.52</b>	<b>1,983.84</b>	<b>2,107.49</b>	<b>2,569.52</b>	<b>2,107.49</b>	<b>8,230.79</b>
<b>II Expenses</b>						
Cost of Material Consumed	2,248.65	1,526.39	1,902.71	2,248.65	1,902.71	6,986.34
Change In Inventories	(1.64)	22.01	(19.08)	(1.64)	(19.08)	48.65
Employee benefit expenses	57.28	13.94	53.63	57.28	53.63	180.05
Finance costs	15.02	11.04	13.38	15.02	13.38	55.69
Depreciation and amortization expenses	22.32	23.83	20.91	22.32	20.91	87.42
Payment to NSE						
Other expenses	165.29	236.80	96.51	165.29	96.51	573.03
<b>Total expenses</b>	<b>2,506.92</b>	<b>1,834.01</b>	<b>2,068.06</b>	<b>2,506.92</b>	<b>2,068.06</b>	<b>7,931.18</b>
<b>III Profit/(Loss) before exceptional items and tax</b>	<b>62.60</b>	<b>149.83</b>	<b>39.43</b>	<b>62.60</b>	<b>39.43</b>	<b>299.61</b>
<b>IV Exceptional items</b>						
<b>V Profit/(Loss) before tax</b>	<b>62.60</b>	<b>149.83</b>	<b>39.43</b>	<b>62.60</b>	<b>39.43</b>	<b>299.61</b>
<b>VI Tax expenses</b>						
a) Current tax	15.20	59.86		15.20		87.50
b) Deferred tax	-0.58	1.51	0.76	(0.58)	0.76	4.01
b) Mat Credit						
<b>VII Net Profit/(Loss) for the period/year</b>	<b>46.82</b>	<b>91.48</b>	<b>40.19</b>	<b>46.82</b>	<b>40.19</b>	<b>216.12</b>
<b>VIII Other comprehensive income (net of tax) loss:</b>						
		59.55	(163)	-	(163)	(103.22)
<b>Total other comprehensive income</b>		59.55				
<b>Total comprehensive income for the period/year (VII+VIII)</b>	<b>46.82</b>	<b>151.03</b>	<b>(122.58)</b>	<b>46.82</b>	<b>(122.58)</b>	<b>112.90</b>
<b>X Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>3,444.87</b>	<b>1,752.27</b>	<b>1,752.27</b>	<b>3,444.87</b>	<b>1,752.27</b>	<b>1,752.27</b>
<b>XI Other equity (excluding revaluation reserve)</b>	<b>5,104.74</b>	<b>2,518.51</b>	<b>2,292.02</b>	<b>5,104.74</b>	<b>2,292.02</b>	<b>2,518.51</b>

XII	EPS in Rs. (Face Value of Rs.10/- each)*							
	-Basic	0.03	0.10	0.23	-	0.03	0.23	0.25
	-Diluted	0.03	0.10	0.23	0.03	0.23	0.23	0.25

**Notes:**

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 09.08.2024 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

**Place : Mohali**  
**Date : 09/08/2024**


For Ajooni Biotech Limited  
  
**Jasjot Singh**  
 Managing Director  
 DIN: 01937631



## Statement of Assets and Liabilities

For the Quarter ended on 30th June 2024

PARTICULARS	in Rs. (Lakhs)	
	30TH JUNE 2024	31ST MARCH 2024
<b>I. ASSETS</b>		
<b>(1) Non - Current Assets</b>		
- a) Property, Plant and Equipment	1,016.73	1,031.89
- b) Capital Work In Progress	106.60	92.45
- c) Investment Property		-
- d) Goodwill		-
- e) Other Intangible Assets		-
- f) Intangible Assets Under Development		-
- g) Biological Assets other than Bearer Plants		-
- h) Financial Assets		
(1) Investments	213.63	213.63
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets		
i) Deferred Tax Asset (net)	30.64	31.22
j) Other Non Current Asset	150.00	150.00
<b>(2) Current Assets</b>		
a) Inventories	1,714.35	1,536.73
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	2,352.80	1,295.94
(3) Cash & Cash Equivalent	2,160.41	42.82
(4) Bank Balances other than (iii) above		
(5) Loans	1,632.37	351.42
(6) Other Financial Asset		0.00
c) Current Tax Assets (net)		-
d) Other Current Asset	5.93	5.93
<b>TOTAL</b>	<b>9,383.45</b>	<b>4,752.04</b>

<b>II EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
a) Equity Share Capital	3,444.87	1,752.27
b) Other Equity	5,104.74	2,518.51
<b>(2) Non-Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	158.22	168.20
(2) Trade Payables		
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	11.99	11.99
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
<b>(3) Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	48.58	48.57
(2) Trade Payables	454.80	158.45
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	1.05	1.05
c) Other Current Liabilities	56.50	5.48
d) Current tax liabilities (Net)	102.70	87.50
<b>TOTAL</b>	<b>9,383.45</b>	<b>4,752.04</b>
<b>Place : Mohali</b>	<b>For Ajooni Biotech Limited</b>  <b>Jasjot Singh</b> <b>Managing Director</b> <b>DIN: 01937631</b>	
<b>Date : 09/08/2024</b>		



# Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

## Limited Review Report on Standalone Financial Results

### To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of **M/s. Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30<sup>th</sup> JUNE 2024 (“the Statement”) attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to “Review of Interim Financial Information performed by the independent auditor of the entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (‘ Ind AS’) prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.  
Chartered Accountants



CA Konica Madan  
Partner

M.No 547759

Date : 09.08.2024

UDIN : 24547759BKFMOW1909